(Q35210407)

7 August 2017

1 reference

title

Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation (English)

1 reference

7 August 2017

1 reference

Shing-Yan Ma

1

1 reference

7 August 2017

George K K Lau

series ordinal

2

1 reference

7 August 2017

Vincent C C Cheng

series ordinal

3

1 reference

7 August 2017

Raymond Liang

series ordinal

4

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

44

1 reference

7 August 2017

issue

8

1 reference

7 August 2017

page(s)

1281-1285

1 reference

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Hepatitis B virus infection in allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Treatment of HBV reactivation after withdrawal of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Famciclovir in chronic hepatitis B: results of a dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Nucleoside analogues in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Combination chemotherapy for hepatitis B virus: the final solution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Advances in therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Therapy of chronic hepatitis B: current challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Hepatitis B associated liver failure following bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Loss of HBsAg in chronic hepatitis B carrier following high-dose chemotherapy and autologous peripheral blood stem cell rescue for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Reactivation of chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Hepatitis B virus precore mutations and HBeAg negative reactivation of chronic hepatitis B after interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Significance of anti-HBc IgM in the differential diagnosis of viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Serodiagnosis of recent hepatitis B infection by IgM class anti-HBc

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Lamivudine as initial treatment for chronic hepatitis B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

C ASE R EPORT: Lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083343

10.1080/1042819031000083343

21 January 2018

Identifiers

DOI

1 reference

release_lb7sdwcxdbaxtbyoehyfpwxfya

7 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lb7sdwcxdbaxtbyoehyfpwxfya

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference